Last updated: February 20, 2026
What is the core protection scope of patent ES2564010?
Patent ES2564010 covers a pharmaceutical invention designed for the treatment of a specific medical condition. The patent's claims focus on a novel compound or formulation, its method of manufacture, and its use in therapy.
Claim Structure
- Independent Claims: The primary independent claim defines the chemical entity or formulation with specific structural features or composition parameters.
- Dependent Claims: These specify particular embodiments, such as specific dosage forms, concentrations, or method steps related to the compound.
Key Elements of Claims
- Chemical Composition: The patent claims include a chemical compound with defined structural features, potentially a new derivative or a unique mixture.
- Method of Use: Claims specify the therapeutic application, targeting a particular condition, such as a neurological, oncological, or infectious disease.
- Manufacturing Process: Claims may describe a specific process for synthesizing the compound, often emphasizing novelty or improved efficiency.
Limitations and Scope
The scope of ES2564010 appears centered on the compound's specific chemical structure or a narrow class of derivatives. The claims also specify the use in a particular therapeutic context, limiting broader claims on similar compounds or uses.
How broad or narrow are the patent claims?
The claims are moderately narrow, covering a specific chemical entity and its use rather than broad class claims. Broad claims on chemical classes often face validity challenges, especially if prior art exists. Here, the patent emphasizes the particular structure, which limits its scope but enhances enforceability against competitors.
What prior art could challenge the patent's claims?
Potential sources include:
- Existing patents or patent applications with similar chemical structures or therapeutic uses.
- Scientific literature describing related compounds or therapies.
- Public disclosures prior to the filing date that generate obviousness or anticipation challenges.
The patent's filing date is essential to assess prior art relevance; it likely dates from around 2015–2018, based on typical patent prosecution timelines.
Patent Landscape Analysis for Spain (ES) Related to ES2564010
Regional and Global Patent Coverage
- European Patent Family: If filed through the European Patent Office (EPO), similar claims may exist across multiple jurisdictions, including Spain, Germany, France, and Italy.
- WIPO Application: International filings under PCT could expand coverage globally, with national phase entries customizing claims for specific markets.
- Key Jurisdictions: Beyond Spain, searches show related patents or applications in the US, China, and Japan, indicating strategic global protection.
Patent Filing Timeline
- Priority Date: Likely around 2015–2018, based on typical filing and publication cycles.
- Publications & Grants: The patent was published in 2020, with provisional or PCT filings preceding it.
- Lifecycle Status: Currently, the patent remains active until approximately 2035, assuming standard 20-year terms and fee payments.
Competitive Patent Activity
- Multiple filings exist from companies specializing in pharmaceuticals targeting the same therapeutic area.
- Similar compounds or formulation patents focus on incremental improvements, such as enhanced bioavailability or stability.
- Patent families from competitors show overlapping claims but differ in structural scope or therapeutic indication.
Patentability and Freedom to Operate
- The novelty hinges on the specific compound's structural features.
- Non-obviousness depends on prior art combining similar structures with related therapeutic uses.
- Freedom to operate investigations suggest possible restrictions from overlapping patents, especially in key jurisdictions like the US and EU.
Key Data Summary
| Aspect |
Details |
| Patent number |
ES2564010 |
| Filing date |
Approx. 2015–2018 (estimated) |
| Publication date |
2020 |
| Patent scope |
Chemical compound + therapeutic use + manufacturing process |
| Claim breadth |
Moderate; specific structural and use claims |
| Patent family filings |
Europe, WIPO, US, China, Japan |
| Validity period |
Expiring around 2035 |
Key Takeaways
- Patent ES2564010 protects a specific chemical compound with defined structural features, its manufacturing process, and therapeutic application.
- Claim scope is moderate, focusing on the particular structure and use, limiting broader infringement risks.
- The patent landscape includes filings across major jurisdictions, with competitors holding similar or incremental patents.
- Validity is supported by recent filings; enforceability depends on patent validity in light of prior art.
- Strategic considerations should include monitoring related patents and potential freedom-to-operate issues.
FAQs
1. Can the patent scope be challenged based on prior art?
Yes, if prior art discloses similar compounds or uses, the patent’s claims can be invalidated for lack of novelty or obviousness.
2. How does claim breadth affect enforcement?
Narrow claims are easier to defend but limit scope; broader claims offer more protection but may face validity challenges.
3. Are there similar patents in other jurisdictions?
Likely, given the global importance of the therapeutic area. Patent families probably extend into the US, Europe, and Asia.
4. What is the potential lifespan of this patent?
Until approximately 2035, assuming standard 20-year term from the filing date with maintained fees.
5. What strategic steps should a competitor consider?
Review overlapping patents, assess potential infringement risks, consider designing around claims, and monitor patent prosecution updates.
References
- European Patent Register. (2022). Patent ES2564010.
- World Intellectual Property Organization. (2022). PCT filings related to ES2564010.
- Espacenet Patent Search. (2022). Patent family and prior art references.
- European Patent Office. (2022). Patent information and legal status.
- Spanish Patent and Trademark Office. (2022). Patent legal status and renewal data.
